Exchange: NASDAQ·Updated 07:30 PM EDT
CING logo

CING Cingulate Inc

$5.07
$0.21
(4.05%)
Today
Closed $4.98
$0.09
(1.81%)
After Hours
Mkt Cap$72.42M
Vol76,665.00

About CING

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.
73

Bullish Sentiment

How do you feel about CING?

Torben96
$CING Results: High-resolution dissolution profiling demonstrated consistent and reproducible trimodal release behavior across all compression DOE batches. All formulations met predefined dissolution specifications at each time point, including 40 min (NLT 26%), 2:30 h (25-45%), 5:30 h (65-95%), and 8:30 h (NLT 90%). Observed average release ranged from approximately 33-38% at early time points, 35-39% at intermediate time points, 71-86% at mid-phase, and 100-109% at late phase across batches (n=6-12). Inter-batch variability remained low with narrow dissolution ranges across the design space. Compression force showed minimal impact on early-phase release but contributed to modest variation in late-phase (third pulse) release behavior, indicating a controlled process sensitivity within the EBL-driven release architecture.
1
25
Bob_Coyle
$CING For those that know how to look, there is very important information out there. I've been very significantly increasing my position and exposure with more to go.
25
stockchacing
$CING Monday maybe last opportunity to buy below $5… just saying… depends when Shane releases the biest or someone else might do too … watch for 10/27! I am excited !!!! 😎💪
1
12
Slyfox24
$CING Resubmission by the end of the year likely. Approved around June. Minor dilution to pay for expenses past June. Stock will jump on resubmission and retrace a bit until May ish then back up as approval nears in June. Approval will be a huge catalyst. Now is a good time to add before the news. Bullish
15
Mattt6
$CING it wouldn’t let me buy $40000 worth all at once due to volume. Had to do 2 separate 20000 buys and only 1 fully filled so far
12
TheDenniSystem
$CING why are you still here? Nobody cares bro and you’re not helping anybody. It goes to $4 we just buy more
9
trader_jin_
$CING Waiting a bit longer is good news IMO, because it gives management more time to address everything at the factory and increases the chances that the resubmission receives a Class 1 review.
6
afgncap
$CING i look through the usernames posting in this ticker right now and im like.... why use ST? Im already talking to these same people elsewhere lol
4
activehybrid
$CING where are you mofos who laughed at me saying we are not going to see low 4s and below 4? Hahahahahahah
1
1
activehybrid
$CING you need to artificially increase the price to short sell That’s why we see the price going up (above 5 ) then going around 4 There’s no news , why the price goes up to 5.5 then 4.30? It will go below 4 this year
1
chris_stocks
$CING They should change the ticker to SINK because that's all it's doing now. I bought in at $4.76. I should have waited because these new low prices are very attractive.
2
activehybrid
$CING Shane repeatedly saying CMC work is continuing but no road map as cingulate runs out of money by June Since February till now CMC issue fix took 8 months already , short term doesn’t look good Below $4 short term Above $20 long term
2
prismmarketview
🧠 ADHD Awareness Month puts community at the center of care—from families and clinicians to coaches and peers. An estimated 22 million Americans currently have an ADHD diagnosis, including 6.5 million children and 15.5 million adults. Their needs extend beyond prescriptions to treatment access, school and workplace accommodations, and ongoing support. For investors, companies addressing different parts of this care network include: 💊 $CING — Investigational once-daily ADHD medication 🧠 $AIFF — Brain-function assessment technology 🧬 $MYGN — Genetic insights to inform psychiatric prescribing 💤 $VVOS — Pediatric sleep-apnea technology, not an ADHD treatment 🔬 $BWAY — Investigational Deep TMS research in adults with ADHD The key distinction: commercial offerings, regulatory clearances, and investigational treatments are not interchangeable. Clinical evidence, regulatory milestones, and demonstrated revenue matter. #ADHDAwarenessMonth #ADHD #MentalHealth #Biotech
1
jrw06
$CING the only question is now, will she bounce back off $6 and go back to $4 again… or will we break through resistance?
EFhutton420
$CING well likely pick up shares again and $2.50 and below but will start tuning in at $3.50, our original purchase price. The tech works, scale up does not. They need to work w Catalent or whoever the original process engineering firm was. A tablet matrix within another matrix, experiences a myriad of competing forces on compression. Too low it won't hold together, too many foot pounds and you shatter one of the matrices. Plus interface physics. Not an easy task and fix will be pricey. Lilly could likely do it but it might be simply undrugable.
4950Stocks
$CING ‘s top executives enjoy a huge salary - but they have terrible communication skills on their drug updates…

Advertisement|Remove ads.